You are here:Home-Chemical Inhibitors & Agonists-Metabolic Enzyme/Protease-Farnesyl transferase (FTase)-FGTI-2734
FGTI-2734

Chemical Structure : FGTI-2734

CAS No.: 1247018-19-4

FGTI-2734 (FGTI2734)

Catalog No.: PC-73014Not For Human Use, Lab Use Only.

FGTI-2734 (FGTI2734) is a potent, CAAX tetrapeptide RAS C-terminal mimetic as dual farnesyltransferase (FT) and geranylgeranyltransferase-1 (GGT-1) inhibitor with IC50 of 250 and 520 nM, respectively.

Packing Price Stock Quantity
5 mg $228 In stock
25 mg $458 In stock
100 mg $958 In stock
1 g Get quote

Bulk size, bulk discount!

E-mail: sales@probechem.com

Tech Support: tech@probechem.com

Purity & Documentation Purity: >98% (HPLC) Select Batch:

Biological Activity

FGTI-2734 (FGTI2734) is a potent, CAAX tetrapeptide RAS C-terminal mimetic as dual farnesyltransferase (FT) and geranylgeranyltransferase-1 (GGT-1) inhibitor with IC50 of 250 and 520 nM, respectively.
FGTI-2734 inhibits both protein prenylation and membrane localization of KRAS and NRAS in RAS-transformed murine NIH3T3 cells and in mutant KRAS human cancer cells, but not the highly selective FTI-2148 or GGTI-2418.
FGTI-2734 inhibits the prenylation of both HDJ2 and RAP1A.
FGTI-2734 inhibits RAF-1 kinase activity although cytosolic KRAS binds RAF-1, it requires KSR and the membrane environment to fully activate RAF-1.
FGTI-2734 induces apoptosis in mutant KRAS-dependent, but not mutant KRAS-independent human cancer cells.
FGTI-2734 inhibits the in vivo growth of mutant KRAS-dependent but not mutant KRAS–independent human tumors in mouse xenograft models (100 mg/kg, i.p.), also inhibits the growth of mutant KRAS PDXs from patients with pancreatic cancer.

Physicochemical Properties

M.Wt 510.632
Formula C26H31FN6O2S
Appearance Solid
CAS No.
Storage
Solide Powder
-20°C 12 Months; 4°C 6 Months
In Solvent
-80°C 6 Months; -20°C 6 Months
Shipping
Solubility

10 mM in DMSO

Chemical Name/SMILES

N-(2-((4-cyano-2-fluorophenyl)((1-methyl-1H-imidazol-5-yl)methyl)amino)ethyl)-N-(cyclohexylmethyl)pyridine-2-sulfonamide

References

1. Sebti SM, et al. Clin Cancer Res. 2019 Jun 21. pii: clincanres.3399.2018. doi: 10.1158/1078-0432.CCR-18-3399.

Copyright © 2022 probechem.com. All Rights Reserved. probechem Copyright

Contact Us sales@probechem.com

Bulk Inquiry

* Indicates a Required FieldYour information is safe with us.

  • *Product name:
  • *Applicant name:
  • *Email address:
  • *Organization name:
  • *Requested quantity:
  • *Country:
  • *Additional Information:

Get Quote

* Indicates a Required FieldYour information is safe with us.

  • *Product name:
  • *Applicant name:
  • *Email address:
  • *Organization name:
  • *Requested quantity:
  • *Country:
  • Additional Information: